<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011125</url>
  </required_header>
  <id_info>
    <org_study_id>ASKC263-LC-1</org_study_id>
    <nct_id>NCT03011125</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)</brief_title>
  <official_title>A Phase 1 Double-blind, Dose-escalation, Placebo-controlled Tolerance Study in Healthy Chinese Adults After Single Intravenous Administration of Dexlansoprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, dose-escalation, placebo-controlled phase
      1 clinical trial. This study will determine the safety and side-effect profile of an
      investigational dexlansoprazole injection after single intravenous administration in healthy
      Chinese adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, double-blind, dose-escalation, placebo-controlled clinical trial.
      Dose escalation will be proceeded according to 3+3 design in five predefined dosing groups.
      After completion of the 90mg dosing study, dose-escalation will be stopped, even though MTD
      is not be observed. A total of 28 participants is scheduled to be recruited. The whole
      follow-up period for each participant will be 3 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">March 9, 2017</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 days</time_frame>
    <description>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexlansoprazole Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexlansoprazole injection</intervention_name>
    <arm_group_label>Dexlansoprazole Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 Years;

          -  Male (weight ≥50kg) or female (weight ≥45kg);

          -  BMI between 19~28 kg/m2;

          -  Healthy subjects (at screening);

          -  Subject who totally understand the aim and progress of this clinical trial, make
             decision by his/her free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
             trial as judged by the investigator;

          -  Subject who has past or present history of any serious diseases, including (but not
             limited to) digestive, cardiovascular, respiratory, urinary, musculoskeletal,
             endocrine, psychiatric or neurological, hematologic, immunological or metabolic
             disorders;

          -  Medical examination, laboratory tests or ECG judged by the investigator to differ
             significantly from normal clinical values;

          -  HIV, HBV, or syphilis positive;

          -  Drug dependency or abuse;

          -  Heavy smokers (&gt;5 cigarettes per day);

          -  Alcohol use;

          -  Participation in another study with an investigational drug within the last 3 months
             preceding this study;

          -  Blood donation within the last 2 months (&gt;= 400 ml), or have a plan to donate blood
             within 1 month after this study;

          -  Intake of any other drug which might influence the results of the trial during two
             weeks previous to the start of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihua Wu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

